BR112016020987A2 - método de identificação de receptores de aloenxerto renal, kit, conjunto de assinatura gênica, método de seleção de paciente e uso de um agente imunossupressivo - Google Patents

método de identificação de receptores de aloenxerto renal, kit, conjunto de assinatura gênica, método de seleção de paciente e uso de um agente imunossupressivo

Info

Publication number
BR112016020987A2
BR112016020987A2 BR112016020987A BR112016020987A BR112016020987A2 BR 112016020987 A2 BR112016020987 A2 BR 112016020987A2 BR 112016020987 A BR112016020987 A BR 112016020987A BR 112016020987 A BR112016020987 A BR 112016020987A BR 112016020987 A2 BR112016020987 A2 BR 112016020987A2
Authority
BR
Brazil
Prior art keywords
kit
immunosuppressive agent
gene signature
patient selection
signature set
Prior art date
Application number
BR112016020987A
Other languages
English (en)
Other versions
BR112016020987A8 (pt
BR112016020987B1 (pt
Inventor
Barbara Murphy
Weijia Zhang
Philip J O'connell
Original Assignee
Icahn School Med Mount Sinai
Western Sydney Local Health Distr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Western Sydney Local Health Distr filed Critical Icahn School Med Mount Sinai
Publication of BR112016020987A2 publication Critical patent/BR112016020987A2/pt
Publication of BR112016020987A8 publication Critical patent/BR112016020987A8/pt
Publication of BR112016020987B1 publication Critical patent/BR112016020987B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112016020987-7A 2014-03-12 2015-03-12 Método de identificação de receptores de aloenxerto renal e método de seleção de receptor do aloenxerto renal BR112016020987B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951651P 2014-03-12 2014-03-12
US61/951,651 2014-03-12
PCT/US2015/020291 WO2015138803A1 (en) 2014-03-12 2015-03-12 Method for identifying kidney allograft recipients at risk for chronic injury

Publications (3)

Publication Number Publication Date
BR112016020987A2 true BR112016020987A2 (pt) 2017-08-15
BR112016020987A8 BR112016020987A8 (pt) 2021-07-06
BR112016020987B1 BR112016020987B1 (pt) 2023-11-14

Family

ID=54072426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016020987-7A BR112016020987B1 (pt) 2014-03-12 2015-03-12 Método de identificação de receptores de aloenxerto renal e método de seleção de receptor do aloenxerto renal

Country Status (8)

Country Link
US (2) US10941446B2 (pt)
EP (1) EP3117220B1 (pt)
CN (2) CN109207580B (pt)
AU (1) AU2015229270B2 (pt)
BR (1) BR112016020987B1 (pt)
CA (1) CA2942384C (pt)
ES (1) ES2824108T3 (pt)
WO (1) WO2015138803A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229270B2 (en) * 2014-03-12 2020-12-24 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
ES2850281T3 (es) 2014-06-26 2021-08-26 Icahn School Med Mount Sinai Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
WO2017070441A1 (en) * 2015-10-23 2017-04-27 Icahn School Of Medicine At Mount Sinai Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor
WO2017100259A1 (en) * 2015-12-08 2017-06-15 Icahn School Of Medicine At Mount Sinai Pretransplant prediction of post-transplant acute rejection
CN110573629A (zh) * 2017-03-30 2019-12-13 伊利诺伊大学理事会 用于诊断早期胰腺癌的方法和试剂盒
WO2019122303A1 (en) 2017-12-22 2019-06-27 Vib Vzw Predicting chronic allograft injury through ischemia-induced dna methylation
EP3781153A4 (en) 2018-04-16 2022-04-06 Icahn School of Medicine at Mount Sinai METHOD AND KITS FOR PREDICTING ACUTE REJECTION AND RENAL ALLOGraft LOSS USING PRE-TRANSPLANTATION TRANSCRIPTOMIC SIGNATURES IN RECIPIENT BLOOD
EP3983562A1 (en) 2019-06-17 2022-04-20 Vib Vzw Predicting chronic allograft injury through age-related dna methylation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
WO1996039154A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US20030104371A1 (en) * 1997-09-24 2003-06-05 Strom Terry B. Methods of evaluating transplant rejection
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US7955800B2 (en) 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
AU2004213839B2 (en) * 2003-02-14 2010-08-12 Beth Israel Deaconess Medical Center, Inc. Predicting graft rejection
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN101039951A (zh) 2003-11-03 2007-09-19 基因信息公司 肝癌生物标志物
CN1846699A (zh) 2005-04-13 2006-10-18 中南大学湘雅医院 1-(取代苯基)-5-甲基-2-(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
RS53599B1 (en) 2005-05-10 2015-02-27 Intermune, Inc. PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS
EP1731620A1 (en) 2005-06-07 2006-12-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the diagnosis of immune graft tolerance
EP2298932A1 (en) 2005-09-29 2011-03-23 Epigenomics AG Methods and nucleic acids for the analysis of gene expression, in particular methylation of KAAG1, associated with tissue classification
GB0524110D0 (en) 2005-11-28 2006-01-04 Univ Cambridge Tech Biomarkers and methods for identification of agents useful in the treatment of affective disorders
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
MX2008014110A (es) 2006-05-02 2008-11-14 Therakos Inc Metodos y reactivos para detectar la susceptibilidad a la enfermedad del injerto versus el hospedero o mortalidad relacionada con el transplante.
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
US20080274911A1 (en) 2006-11-07 2008-11-06 Burington Bart E Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof
EP2104737B1 (en) 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
KR101007926B1 (ko) 2006-12-27 2011-01-12 (주)레퍼런스바이오랩 표준 발현 유전자를 발굴하기 위한 유전자 발현 데이터처리, 분석 방법
CA2713909C (en) 2008-02-01 2023-12-12 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
JP2011521630A (ja) 2008-05-30 2011-07-28 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア ゲノミクスまたはプロテオミクス発現プロファイリングを用いて腎同種移植の拒絶反応を診断する方法
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
ES2492498T3 (es) 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
EP2389582B1 (en) 2009-01-20 2016-04-06 Cambridge Enterprise Limited Methods for predicting autoimmune disease risk
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
WO2011044511A2 (en) 2009-10-08 2011-04-14 The Trustees Of Columbia University In The City Of New York Rage regulates rock activity in cardiovascular disease
PL2496720T3 (pl) * 2009-11-06 2021-01-11 The Board Of Trustees Of The Leland Stanford Junior University Nieinwazyjna diagnoza odrzucenia przeszczepu u pacjentów z przeszczepem narządu
EP2510116A2 (en) 2009-12-09 2012-10-17 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
ES2798114T3 (es) * 2010-03-25 2020-12-09 Univ Leland Stanford Junior Biomarcadores de proteínas y de genes para el rechazo de trasplantes de órganos
KR20130043104A (ko) * 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
TWI542690B (zh) 2010-05-12 2016-07-21 再生醫學Tx有限責任公司 生物活性腎細胞
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
US20120107825A1 (en) 2010-11-01 2012-05-03 Winger Edward E Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna
CA2827894A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
BR112013032232A2 (pt) * 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
US20130078633A1 (en) 2011-09-22 2013-03-28 ImmuMetrix, LLC Detection of Isotype Profiles as Signatures for Disease
EP2771487A1 (en) 2011-10-27 2014-09-03 Asuragen, INC. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
FI123683B (en) 2011-11-28 2013-09-13 Teknologian Tutkimuskeskus Vtt Process for catalytic oxidation of a natural composition comprising unsaturated fatty acids and / or esters thereof and use of a mixture obtained therefrom to produce mono-, oligo- and / or polyesters
EP4349343A2 (en) 2011-11-30 2024-04-10 Jörn Bullerdiek Expression of mirnas in placental tissue
AU2013207778B2 (en) 2012-01-13 2017-10-12 Genentech, Inc. Biological markers for identifying patients for treatment with VEGF antagonists
US20150242701A1 (en) 2012-09-20 2015-08-27 Sharp Kabushiki Kaisha Image processing device, image display device, image capture device, image printing device, gradation conversion method, and computer readable medium
WO2014055117A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
WO2014071205A1 (en) 2012-11-02 2014-05-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
US20140329704A1 (en) 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same
CN103421905A (zh) 2013-08-20 2013-12-04 张飚 从血液中检测用于诊断脑卒中的microRNA的方法
EP3044333A4 (en) 2013-09-09 2017-08-09 The Scripps Research Institute Methods and systems for analysis of organ transplantation
AU2015229270B2 (en) * 2014-03-12 2020-12-24 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
ES2897004T3 (es) 2014-06-26 2022-02-28 Icahn School Med Mount Sinai Métodos para diagnosticar el riesgo de fibrosis y rechazo de aloinjerto renal
ES2850281T3 (es) 2014-06-26 2021-08-26 Icahn School Med Mount Sinai Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
WO2017100259A1 (en) 2015-12-08 2017-06-15 Icahn School Of Medicine At Mount Sinai Pretransplant prediction of post-transplant acute rejection
WO2017147196A1 (en) 2016-02-22 2017-08-31 Massachusetts Institute Of Technology Methods for identifying and modulating immune phenotypes
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
US20180356402A1 (en) 2017-06-08 2018-12-13 The Cleveland Clinic Foundation Urine biomarkers for detecting graft rejection
EP3781153A4 (en) 2018-04-16 2022-04-06 Icahn School of Medicine at Mount Sinai METHOD AND KITS FOR PREDICTING ACUTE REJECTION AND RENAL ALLOGraft LOSS USING PRE-TRANSPLANTATION TRANSCRIPTOMIC SIGNATURES IN RECIPIENT BLOOD

Also Published As

Publication number Publication date
CN106461679A (zh) 2017-02-22
EP3117220B1 (en) 2020-07-08
CN109207580B (zh) 2022-03-11
WO2015138803A1 (en) 2015-09-17
BR112016020987A8 (pt) 2021-07-06
CA2942384A1 (en) 2015-09-17
US11674181B2 (en) 2023-06-13
AU2015229270A1 (en) 2016-10-20
CA2942384C (en) 2024-01-23
BR112016020987B1 (pt) 2023-11-14
US20170114407A1 (en) 2017-04-27
EP3117220A1 (en) 2017-01-18
EP3117220A4 (en) 2017-08-30
AU2015229270B2 (en) 2020-12-24
CN109207580A (zh) 2019-01-15
ES2824108T3 (es) 2021-05-11
US10941446B2 (en) 2021-03-09
US20210230700A1 (en) 2021-07-29
CN106461679B (zh) 2018-10-09

Similar Documents

Publication Publication Date Title
BR112016020987A2 (pt) método de identificação de receptores de aloenxerto renal, kit, conjunto de assinatura gênica, método de seleção de paciente e uso de um agente imunossupressivo
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
BR112017025828A2 (pt) dispositivo de nó hospedeiro e métodos de uso com o mesmo.
HK1223660A1 (zh) 種測序文庫的構建方法及試劑盒和應用
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
BR112017024899A2 (pt) proteínas de ligação trispecíficas e métodos de uso.
EP3001196B8 (en) Blood testing system and method
BR112016024034A2 (pt) ativadores de canal iônico e métodos de uso
BR112016018521A2 (pt) composição, e, kit.
EP3509907A4 (en) SYSTEMS AND METHODS FOR ANALYZING A CORE BY MEANS OF X-RAY FLUORESCENCE
EP3347695A4 (en) ANALYZE INSTRUMENT, APPROPRIATE SYSTEMS AND METHOD
BR112016030968A2 (pt) análogos de pridopidina, preparação e uso destes
EP3113698A4 (en) Single incision specimen retrieval assembly, method of use, and kit
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
EP3368502A4 (en) ELECTROCHEMICAL HALOGENIZATION AND OXYHALOGENIZATION SYSTEMS AND METHOD
EP3179913A4 (en) System for defining and executing audiometric tests
EP3341021A4 (en) ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
EP3353354A4 (en) MEANS FOR COLLECTING, SAMPLING, AND DIAGNOSING SEASON SAMPLES AND ASSOCIATED METHODS
EP3139163A4 (en) Immunochromotographic analysis kit, immunochromotographic analysis device, and immunochromotographic analysis method
EP3220342A4 (en) Itinerary determination method, itinerary determination program and itinerary determination device
BR112016024806A2 (pt) aplicativo de mensagem privada e métodos associados.
GB201617572D0 (en) Use, method, kit, composition and antibodies
GB201620377D0 (en) Systems, methods, and kits for cleansing an ocular region
EP3254297A4 (en) Probes, systems, cartridges, and methods of use thereof

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2015, OBSERVADAS AS CONDICOES LEGAIS